With recent advances and approvals of immuno-oncology (IO) agents, pharmaceutical companies are striving to strategize and to allocate necessary resources to IO discovery, as well as to the clinical development and commercialization efforts in this exploding therapeutic area. Cambridge Healthtech Institute’s Inaugural IO Pharma Congress is designed to bring together major stakeholders from biopharmaceutical companies to discuss challenges and solutions in the areas of emerging IO targets and modalities, combination immunotherapy, clinical trials, biomarkers, business strategy and more. The Congress is part of Cambridge Healthtech Institute’s World Pharma Week: the premier meeting place for pharmaceutical decision makers!

Conference Programs

June 18-19

▶ Preclinical Strategies, Models & Tools in Oncology (Shared Conference with World Preclinical Congress)

▶ Immuno-Oncology Biomarkers 1: Predictive Biomarkers and Companion Diagnostics (Shared Conference with Biomarker World Congress)

▶ Clinical Innovation for Combination Immunotherapy

▶ Introductory Immunology for Cancer and Autoimmune Drug Discovery

June 19-20

▶ Patient-Derived Tumor Organoids (Shared Conference with World Preclinical Congress)

▶ Small Molecules for Immuno-Oncology Therapeutics (Shared Conference with World Preclinical Congress)

▶ Cancer Immunotherapy Models (Shared Conference with World Preclinical Congress)

▶ Immuno-Oncology Biomarkers 2: Immune Profiling and Immune Monitoring(Shared Conference with Biomarker World Congress)

Featured Speakers

David H. Sherr, PhD,

David H. Sherr, PhD,
Professor, Pathology and Laboratory Medicine, Boston University

Rakesh Dixit, PhD, DABT,

Rakesh Dixit, PhD, DABT,
President & CEO, Bionavigen

Roy Baynes, MD, PhD,

Roy Baynes, MD, PhD,
Senior Vice President and Head, Global Clinical Development, CMO, Merck Research Laboratories

Mark C. Poznansky, MD, PhD,

Mark C. Poznansky, MD, PhD,
Director, Vaccine & Immunotherapy Center, Massachusetts General Hospital; Associate Professor, Harvard Medical School

Jonathan Cheng, MD,

Jonathan Cheng, MD,
Vice President & Oncology Therapeutic Area Head, Merck

Bruno Gomes, DVM, PhD,

Bruno Gomes, DVM, PhD,
Global Head of Biomarkers Oncology, Roche

Jill Loftiss

Jill Loftiss
Head, Clinical Operations & Oncology, MedImmune

Adessi Céline, PhD,

Céline Adessi, PhD,
Senior Group Director, Product Development, Safety Science Oncology, Licensing and Early Development, F. Hoffmann-La Roche

George A. Green IV, PhD,

George A. Green IV, PhD,
Executive Director, Precision Medicine, Head, Pharmacodiagnostics, Translational Medicine, Bristol-Myers Squibb

Michael Woo

Michael Woo, PhD,
Head, Search & Evaluation, Immuno-Oncology, Business Development & Licensing, Novartis Institutes for BioMedical Research, Inc.

Daniela Cipolletta, PhD,

Daniela Cipolletta, PhD,
Lab Head, Investigator III, Immuno-Oncology, Novartis Institutes for BioMedical Research

Elaine Pinheiro, PhD,

Elaine Pinheiro, PhD,
Senior Principal Scientist, Oncology, Merck